More specifically, we employed a highly aggressive breast cancer cell line (BT549) treated with EZH2 inhibitor (Dznep) for RNA sequencing assays, attempting to identify its downstream target genes in BC in vitro. The gene discussed is EZH2; the disease is breast carcinoma.